It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The health hazards of smoking are well recognised and recently knowledge about the harmful effects of nicotine and snus is accumulating. We investigated the factors increasing the willingness of young Finnish males to quit snus and cigarette smoking. We conducted a questionnaire study conducted in 3 out of 16 Finnish Defence Forces units which included 6508 male conscripts, of whom 4706 responded (response rate 72%, mean age 19.4 years). Factors related to the willingness to quit use were analysed by ordinal regression models. Backward selection following the Akaike information criterion (AIC) was used for the model. The prevalence figures of daily snus use and smoking were 17% and 25%, respectively. 16% of the daily snus users were also daily smokers and 29% were occasional smokers. Multivariate analysis showed that the willingness to quit snus use was associated with the perception of health hazards (OR 3.09, 95% CI 1.94–4.93) and with ≥ 2 quit attempts (OR 3.63, 95% CI 2.44–5.40). The willingness to quit smoking was associated with ≥ 2 quit attempts (OR 3.22, 95% CI 2.32–4.49), and with advice to quit smoking (OR 1.65, 95% CI 1.17–2.32). We created a brief two-question assessment model for snus dependence. With this model, nicotine dependence of daily snus users was congruent with that of nicotine dependence of smokers. A direct comparison with serum cotinine levels is necessary before our assessment model can be used as a proxy for dependence. Regular snus use predisposes to nicotine addiction and accumulated health hazards. Our findings underscore the importance of health promotion efforts in early adolescence and of active support for quitting snus use. Easily applicable tools to estimate nicotine addiction are needed for everyday clinical use.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Finnish Defence Forces, Helsinki, Finland (GRID:grid.418253.9) (ISNI:0000 0001 0340 0796); University of Helsinki, Doctoral Programme in Population Health, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
2 Finnish Lung Health Association (FILHA), Helsinki, Finland (GRID:grid.478980.a)
3 The Finnish Defence Forces, Helsinki, Finland (GRID:grid.418253.9) (ISNI:0000 0001 0340 0796)
4 National Institute for Health and Welfare, Helsinki, Finland (GRID:grid.14758.3f) (ISNI:0000 0001 1013 0499)
5 Finnish Medicines Agency Fimea, Helsinki, Finland (GRID:grid.490668.5) (ISNI:0000 0004 0495 5912); Turku University Hospital and University of Turku, Division of Medicine, Department of Oncology, Turku, Finland (GRID:grid.410552.7) (ISNI:0000 0004 0628 215X)
6 Finnish Lung Health Association (FILHA), Helsinki, Finland (GRID:grid.478980.a); Turku University Hospital and University of Turku, Division of Medicine, Department of Pulmonary Diseases and Clinical Allergology, Turku, Finland (GRID:grid.410552.7) (ISNI:0000 0004 0628 215X)




